NervGen Pharma Corp. Common stock

NASDAQ: NGEN · Healthcare · Biotechnology

Canadian filerHQ West Vancouver, BCCIK 0001751912Reports USD

#1 of 1,394 Healthcare companies by revenue

EA Score

——

FH 27DQ —GM —SS 37

v0.1 · 35/100 weight · pillars only

↑ market scale, Altman-Z · ↓ return on equity, filing timeliness

Methodology →

Revenue TTM

Rev growth YoY (TTM)

needs 8 qtrs

Net income (FY)

-$31.6M

Employees

Market cap

$174.2M

Financials — latest annual

SEC EDGAR · USD-normalized

ConceptUSDNativeFY

Net income-$31.6M-44.1M CAD2025

Total assets$16.9M23.2M CAD2025

Liabilities$14.4M19.7M CAD2025

Revenue by segment

No segmentation disclosed for this filer. n/a

The read

NervGen Pharma Corp. Common stock earned -$31.6M in FY2025 net income.

Peers · Healthcare

Auxly Cannabis Group Inc.76B+Stereotaxis, Inc.55C Aurora Cannabis Inc.——Coherus Oncology, Inc.62C

Key facts

CEOAdam H. Rogers

SectorHealthcare

IndustryBiotechnology

HeadquartersWest Vancouver, BC

ExchangeNASDAQ: NGEN

Employees7

IPO date2021-02-08

Latest filings

6-K2026-07-02 6-K2026-06-01 6-K2026-05-26 6-K2026-05-22 6-K2026-05-18 6-K2026-05-15 6-K2026-04-27 40-F2026-03-31

Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.